Ohnishi T, Takeda E, Yogita S, Miyake H, Kinoshita T, Terashima Y, Matsumoto T, Tashiro S
First Department of Surgery, University of Tokushima, School of Medicine, Japan.
Jpn J Clin Oncol. 2000 Sep;30(9):410-3. doi: 10.1093/jjco/hyd105.
Alendronate, a bisphosphonate compound, lowers serum calcium in patients with cancer-associated hypercalcemia through its inhibitory effect on bone resorption and as a result symptoms associated with hypercalcemia improve. This study was carried out to investigate the effects of alendronate in patients with hypercalcemia due to bone metastasis of hepatocellular carcinoma (HCC). Two patients were evaluated. Their corrected serum calcium and alpha-fetoprotein (AFP) levels and their computed tomography (CT), bone scintigraphy and magnetic resonance imaging (MRI) findings were evaluated before and during alendronate treatment. After treatment, not only the corrected serum calcium levels but also AFP levels and bone pain decreased; in addition, the regression of the metastatic focus was noted in the MRI analysis. These tumor inhibitory effects of alendronate have not been reported in HCC before; and alendronate might serve to prevent bone metastases in patients with HCC. In conclusion, two patients who developed hypercalcemia associated with bone metastasis after surgery for HCC were treated with alendronate and they experienced alleviation of the pain due to bone metastasis, improvement of their quality of life and a marked decrease in AFP levels with tumor regression.
阿仑膦酸钠是一种双膦酸盐化合物，通过抑制骨吸收降低癌症相关性高钙血症患者的血清钙水平，从而改善与高钙血症相关的症状。本研究旨在探讨阿仑膦酸钠对肝细胞癌（HCC）骨转移所致高钙血症患者的影响。对两名患者进行了评估。在阿仑膦酸钠治疗前及治疗期间，评估了他们的校正血清钙和甲胎蛋白（AFP）水平以及计算机断层扫描（CT）、骨闪烁显像和磁共振成像（MRI）结果。治疗后，不仅校正血清钙水平下降，AFP水平和骨痛也减轻；此外，MRI分析显示转移灶缩小。阿仑膦酸钠的这些肿瘤抑制作用此前在HCC中尚未见报道；阿仑膦酸钠可能有助于预防HCC患者发生骨转移。总之，两名HCC术后发生与骨转移相关高钙血症的患者接受了阿仑膦酸钠治疗，他们骨转移所致疼痛减轻，生活质量改善，AFP水平显著下降且肿瘤缩小。
